Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Tablet Health vs Wisp

Tablet Health
Graded #495

Lower grade

vs+16.800000000000004
Wisp
Graded #243

Higher grade

The verdict

Wisp takes it — 64.4/100 to 47.6/100.

Wisp grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWisp +5
45
50
Dose & formulationWisp +25
51
76
Clinical oversightWisp +45
37
82
Labs & monitoringWisp +3
50
53
FulfillmentWisp +9
57
66
Contract termsEven
55
55
Tablet Health · left barWisp · right bar

The numbers

MetricTablet HealthWisp
WeighScore47.6/10064.4/100
GradeCC
Scorecard rank#495#243
SemaglutideNot disclosed$225/mo (compounded oral)
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Tablet Health

Graded #495 · C

Strengths

  • LegitScript Certified
  • Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
  • Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
  • Mid-tier pricing starting $179–$299/mo across all four product variants
  • No commitment — cancel anytime

Where it loses points

  • States served not published — you must complete the intake quiz to learn eligibility
  • No founder, CEO, medical director, or pharmacist-in-charge named anywhere
  • No BBB profile found
  • Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Wisp

Graded #243 · C

Strengths

  • Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
  • LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
  • Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary

Where it loses points

  • The $99/mo tirzepatide figure is a consultation-and-care subscription, not the medication: Zepbound is filled at a pharmacy of your choice at its own cost, which Wisp does not publish
  • The compounded semaglutide option is sublingual drops, which Wisp itself describes as less effective than injection
  • Brand-name access is a prescription, not a dispensed product, so the drug cost is outside anything quoted here

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard